Mabion S.A. (MAB) - Total Liabilities
Based on the latest financial reports, Mabion S.A. (MAB) has total liabilities worth zł70.76 Million PLN (≈ $19.47 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check MAB financial resilience to evaluate the company's liquid asset resilience ratio.
Mabion S.A. - Total Liabilities Trend (2009–2025)
This chart illustrates how Mabion S.A.'s total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see balance sheet size of Mabion S.A..
Mabion S.A. Competitors by Total Liabilities
The table below lists competitors of Mabion S.A. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
M.J. International Co Ltd
TW:8466
|
Taiwan | NT$3.28 Billion |
|
Angus Ventures Inc
V:GUS
|
Canada | CA$1.77 Million |
|
Brixton Metals Corporation
V:BBB
|
Canada | CA$3.21 Million |
|
Thirdeye Systems Ltd
TA:THES
|
Israel | ILA31.28 Million |
|
Reckon Ltd
AU:RKN
|
Australia | AU$31.24 Million |
|
Biohit Oyj B
HE:BIOBV
|
Finland | €4.90 Million |
|
DONGJIANG ENVIRONMENTAL H
F:DGN
|
Germany | €7.09 Billion |
|
Mtag Group Berhad
KLSE:0213
|
Malaysia | RM10.61 Million |
Liability Composition Analysis (2009–2025)
This chart breaks down Mabion S.A.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Mabion S.A. (MAB) net asset quality to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.31 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.81 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.64 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Mabion S.A.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Mabion S.A. (2009–2025)
The table below shows the annual total liabilities of Mabion S.A. from 2009 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | zł55.08 Million ≈ $15.16 Million |
+14.68% |
| 2024-12-31 | zł48.03 Million ≈ $13.22 Million |
-46.92% |
| 2023-12-31 | zł90.48 Million ≈ $24.90 Million |
-17.50% |
| 2022-12-31 | zł109.67 Million ≈ $30.18 Million |
-16.24% |
| 2021-12-31 | zł130.92 Million ≈ $36.03 Million |
-15.92% |
| 2020-12-31 | zł155.71 Million ≈ $42.85 Million |
+15.23% |
| 2019-12-31 | zł135.12 Million ≈ $37.19 Million |
+31.73% |
| 2018-12-31 | zł102.58 Million ≈ $28.23 Million |
-24.91% |
| 2017-12-31 | zł136.60 Million ≈ $37.60 Million |
+56.09% |
| 2016-12-31 | zł87.52 Million ≈ $24.09 Million |
+32.78% |
| 2015-12-31 | zł65.91 Million ≈ $18.14 Million |
-86.36% |
| 2014-12-31 | zł483.33 Million ≈ $133.02 Million |
+106.43% |
| 2013-12-31 | zł234.13 Million ≈ $64.44 Million |
-89.07% |
| 2012-12-31 | zł2.14 Billion ≈ $589.36 Million |
+32462.22% |
| 2011-12-31 | zł6.58 Million ≈ $1.81 Million |
+282.47% |
| 2010-12-31 | zł1.72 Million ≈ $473.23K |
+306.55% |
| 2009-12-31 | zł422.95K ≈ $116.40K |
-- |
About Mabion S.A.
Mabion S.A., a biopharmaceutical company, provides contract development, analytics, and manufacturing services for biologics in Poland. It offers drug substance manufacturing, process development, analytics, and cell line development services. The company also provides medicines for cancer, autoimmune diseases, rare diseases, and other diseases. The company was founded in 2007 and is headquartere… Read more